Allergy

To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.

The field of allergy medicine this year saw a variety of developments, including the FDA approvals of neffy and omalizumab as well as new data on immunotherapy.

These data expanded upon limited real-world data on retention of dupilumab past 2 years of treatment for patients with atopic dermatitis.

These interim data resulted from the JADE REAL study, with 72-week results suggesting rapid improvements in eczema severity for adults and adolescents.

Kim, Sindher, Huffaker spoke with HCPLive about some of the year’s most important developments in the food allergy space, namely the approvals of omalizumab and neffy.

Findings suggest an association between food allergies and atopic dermatitis control and persistence.

These findings highlight the safety and effectiveness of ESO-101 among adult patients with active eosinophilic esophagitis (EoE).

This interview featured a discussion with Browning regarding his team’s findings prior to the FDA approval of tapinarof cream 1% for atopic dermatitis.

Needle-free treatments, such as Neffy and FluMist, offer promising alternatives for children and adults with needle phobia, ensuring access to critical care.

The submission of roflumilast’s supplemental New Drug Application to the FDA by Arcutis follows the conclusion of the INTEGUMENT-PED and INTEGUMENT-OLE studies.

The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.

This approval announcement by Galderma follows the previous FDA approval of nemolizumab for prurigo nodularis.

This interim analysis highlights positive findings from the Measure Up 1 and 2 studies regarding upadacitinib for patients with atopic dermatitis.

These data provide insight into characteristics of those who choose to discontinue systemic therapies for eczema.

This assessment of dupilumab for pediatric and adult patients with moderate-to severe eczema treated for up to 5 years confirms the drug efficacy and safety across age groups.

These long-term results from the ADjoin trial show that long-term lebrikizumab therapy may improve sleep disturbances, pruritus, and skin symptoms, using POEM as an assessment tool.

Investigators looked at the effects of the exposome among patients with atopic dermatitis in order to better understand the influence of such elements as obesity and microorganisms.

In this analysis, investigators determined that the eliciting dose of an allergen may be an unpredictable marker for the severity of an allergic reaction.

These data highlight some of the most notable findings related to airline travel issues among those with food allergies or with family members with such allergies.

In this iteration of the Month in Review series, a list of highlighted stories in the allergy and immunology space covered in the month of November is provided.

An overview and landing page for future installments from HCPLive's 8th annual This Year in Medicine Series.

The FDA affirmed the planned NDA content and format for Anaphylm expected in Q1 2025, without requiring additional adult clinical trials before submission.

In this analysis, egg consumption among pregnant mothers was found to be insufficient for the development of oral tolerance to eggs among infants at 1 year of age.

In this analysis, the investigators systematically assessed links between the macronutrient profiles of common allergenic foods and corresponding prevalence of food allergy.

This analysis evaluated the frequency of peanut-sensitized infants and toddlers being sensitized to other types of nuts.